2. Search Result
Search Result
Results for "

primary neurons

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

2

MCE Kits

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122742
    HBT1

    		iGluR Neurological Disease
    HBT1 is an effective AMPA receptor AMPA-R potentiator. HBT1 specifically binds to the ligand-binding domain (LBD) of AMPAR and enhances receptor activity only when AMPA is present., HBT1 has almost no agonistic effect (i.e., reaching the optimal concentration, and then the efficacy decreases as the concentration continues to increase) compared with traditional AMPA-R potentiator, avoiding the bell-shaped reaction of brain-derived neurotrophic factor (BDNF) production in primary neurons. HBT1 can be applicable to a wider range of neurological and psychiatric diseases (such as depression, Alzheimer's disease, etc.) .
    HBT1
  • HY-B0596
    Taltirelin
    1 Publications Verification

    TA-0910

    		 Thyroid Hormone Receptor Apoptosis Neurological Disease Endocrinology
    Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC50 at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca 2+ concentration (Ca 2+ release) with an EC50 value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .
    Taltirelin
  • HY-B0596A
    Taltirelin acetate
    1 Publications Verification

    TA-0910 acetate

    		 Thyroid Hormone Receptor Apoptosis Neurological Disease Endocrinology
    Taltirelin acetate (TA-0910) is an acetate form of Taltirelin (TA-0910). Taltirelin (TA-0910) is an orally effective analogue of thyrotropin releasing hormone (TRH) and a TRH receptor (TRH-R) superagonist (IC50 at 910 nM). Taltirelin can cross the blood-brain barrier. Taltirelin stimulates an increase in cytosolic Ca 2+ concentration (Ca 2+ release) with an EC50 value of 36 nM. Taltirelin increases cell viability and reduces apoptosis in SH-SY5Y cells and primary rat mesencephalic neurons treated with MPP+ (HY-W008719) or Rotenone (HY-B1756). Taltirelin has neuroprotective effects in both cellular and animal models of Parkinson's disease. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue .
    Taltirelin acetate
  • HY-120079
    MSN-125
    3 Publications Verification

    		 Bcl-2 Family Apoptosis Cancer
    MSN-125 is a potent Bax and Bak oligomerization inhibitor. MSN-125 prevents mitochondrial outer membrane permeabilization (MOMP) with an IC50 of 4 μM. MSN-125 potently inhibits Bax/Bak-mediated apoptosis in HCT-116, BMK Cells, and primary cortical neurons, protects primary neurons against glutamate excitotoxicity .
    MSN-125
  • HY-122672A
    Adhesamine diTFA

    		FAK Neurological Disease
    Adhesamine diTFA is a dumbbell-shaped molecule that activates the MAPK/FAK pathway. Adhesamine promotes the adhesion and growth of mammalian cells, accelerates the differentiation of primary cultured mouse hippocampal neurons, and enhances their survival rate .
    Adhesamine diTFA
  • HY-119820
    Xaliproden free base

    SR57746A free base

    		 5-HT Receptor Neurological Disease
    Xaliproden free base is an orally active and selective 5-HT1A receptor agonist. Xaliproden free base shows analgesic effect against acute tonic nociceptive pain and has neuroprotective effects. Xaliproden free base has an acute inhibitory effect on paclitaxel (HY-B0015)-induced mechanical allodynia by inhibiting the excessive response of primary afferent neurons .
    Xaliproden free base
  • HY-122672
    Adhesamine

    		FAK Neurological Disease
    Adhesamine, dumbbell-shaped molecule, activates MAPK/FAK pathway. Adhesamine promotes adhesion and growth of mammalian cells. Adhesamine accelerates the differentiation and improves the survival of mice hippocampal neurons in primary culture .
    Adhesamine
  • HY-174311
    GT-02216

    		Glycosidase Neurological Disease
    GT-02216 can bind to GCase allosterically and enhance its activity. GT-02216 enhances the activity of GCase in primary human fibroblasts. GT-02216 reduces the Tau accumulation in mutant GBA1 fibroblasts. GT-02216 protects the hippocampal primary neurons challenged with Tau oligomer in rat model .
    GT-02216
  • HY-139008
    RC363

    		Glutathione Peroxidase Others
    RC363 is a novel probucol analog with the activity to protect mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death (ferroptosis) and increase glutathione peroxidase (GPx) 1 levels and activity.
    RC363
  • HY-139012
    RC574

    		Ferroptosis Glutathione Peroxidase Others
    RC574 is a novel probucol analog with the activity to protect mouse hippocampal cells and primary cortical neurons from glutamate-induced oxidative cell death (ferroptosis) and increase glutathione peroxidase (GPx) 1 levels and activity.
    RC574
  • HY-B0553
    Methazolamide
    4 Publications Verification

    L584601

    		 Carbonic Anhydrase Apoptosis Reactive Oxygen Species (ROS) Caspase Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage .
    Methazolamide
  • HY-173142
    Neuroprotective agent 7

    		Drug Derivative Neurological Disease
    Neuroprotective agent 7 (Compound 13) is a BBB-penetrable neuroprotective agent. Neuroprotective agent 7 has a powerful neuroprotective effect and can reduce the cerebral infarct area in the MCAO rat model. Neuroprotective agent 7 can be used in the research of diseases such as cerebral ischemia .
    Neuroprotective agent 7
  • HY-162653
    SGC-CDKL2/AAK1/BMP2K-1

    		Others
    SGC-CDKL2/AAK1/BMP2K-1 (Compound 9) is a potent and selective CDKL2 (Cyclin-dependent kinase-like 2) inhibitor with an IC50 value of 460 nM. CDKL2 is involved in various biological processes such as tumorigenesis, development, and viral infections. SGC-CDKL2/AAK1/BMP2K-1 serves as a powerful tool for studying the biological functions of CDKL2 and holds promise for research in fields related to cancer, infections, and other diseases .
    SGC-CDKL2/AAK1/BMP2K-1
  • HY-P1192
    GR-73632

    		Neurokinin Receptor Neurological Disease Endocrinology
    GR-73632 is a novel tachykinin neurokinin 1 (NK-1) receptor agonist . GR-73632 acts directly on the peripheral terminals of primary sensory neurons through NK1 receptor which convey itch signals .
    GR-73632
  • HY-122635A
    T-448

    		Histone Demethylase Neurological Disease
    T-448 is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons .
    T-448
  • HY-145468
    GPR52 antagonist-1

    		GPR52 Neurological Disease
    GPR52 antagonist-1 (Compound 43) is a GPR52 antagonist with an IC50 of 0.63 μM. GPR52 antagonist-1 reduces mHTT (mutant huntingtin protein) levels by targeting GPR52 and promotes survival of mouse primary striatal neurons .
    GPR52 antagonist-1
  • HY-B1740
    Pregnenolone acetate

    		Microtubule/Tubulin Neurological Disease
    Pregnenolone acetate (compound #43), a nonmetabolized Pregnenolone (HY-B0151) analog, can promote neurite extension and induce a change in growth cone morphology in primary cultures of cerebellar granule neurons. Pregnenolone acetate, a neurosteroid, increases microtubule polymerization. Pregnenolone acetate has the potential for neurodevelopmental diseases research .
    Pregnenolone acetate
  • HY-121252
    Dopal

    		α-synuclein Neurological Disease
    Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species (ROS), and triggers aggregation of α-synuclein. Dopal elicits α-synuclein accumulation and hampers α-synuclein clearance in primary neurons .
    Dopal
  • HY-N15352
    C20 Sphingomyelin (d18:1/20:1)

    		Liposome Neurological Disease
    C20 Sphingomyelin (d18:1/20:1) (Compound SM:20:1) is a sphingomyelin. C20 Sphingomyelin (d18:1/20:1) is promising for research of motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) .
    C20 Sphingomyelin (d18:1/20:1)
  • HY-122635
    T-448 free base

    		Histone Demethylase Neurological Disease
    T-448 free base is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC50 of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons .
    T-448 free base
  • HY-121636
    Resolvin D2
    4 Publications Verification

    RvD2

    		 TRP Channel Infection Neurological Disease Inflammation/Immunology
    Resolvin D2 is a metabolite of docosahexaenoic acid (DHA), with anti-inflammatory, anti-infective activities. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Resolvin D2 is a remarkably potent inhibitor of TRPV1 (IC50 = 0.1 nM) and TRPA1 (IC50 = 2 nM) in primary sensory neurons .
    Resolvin D2
  • HY-125693
    L685818

    		Fungal Infection Neurological Disease
    L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans .
    L685818
  • HY-18638
    TCID
    4 Publications Verification

    4,5,6,7-Tetrachloroindan-1,3-dione

    		 Deubiquitinase Neurological Disease
    TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC50 of 0.6 μM . TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons .
    TCID
  • HY-126436A
    Poly-L-ornithine hydrobromide (MW 30000-70000)

    L-Ornithine homopolymer hydrobromide (MW 30000-70000)

    		 Biochemical Assay Reagents Neurological Disease
    Poly-L-ornithine hydrobromide (MW 30000-70000) is a poly-lysine derivative with a molecular weight of 30000-70000. Poly-L-ornithine hydrobromide (MW 30000-70000) binds to the surface of cell culture vessels through positively charged amino acid residues to form a coating that promotes cell adhesion and provides cells with a matrix environment required for growth. Poly-L-ornithine hydrobromide (MW 30000-70000) is used as a coating agent in cell culture. Poly-L-ornithine hydrobromide (MW 30000-70000) can be used for the study of primary culture of neurons (such as dopaminergic neurons and oligodendrocytes) .
    Poly-L-ornithine hydrobromide (MW 30000-70000)
  • HY-121252A
    Dopal (purity>80%)

    		α-synuclein Neurological Disease
    Dopal (purity>80%) is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal (purity>80%) can generate reactive oxygen species (ROS), and triggers aggregation of α-synuclein. Dopal (purity>80%) elicits α-synuclein accumulation and hampers α-synuclein clearance in primary neurons .
    Dopal (purity>80%)
  • HY-100458
    SCR-4026

    		NO Synthase Neurological Disease
    SCR-4026 is a neuroprotective agent with blood-brain barrier penetration ability. SCR-4026 exerts neuroprotective effects by disrupting the interaction between neuronal nNOS and PSD9, with an IC50 of 6.3 μM. SCR-4026 alleviates N-methyl-D-aspartate (NMDA)-induced excitotoxic damage in primary cortical neurons, and also protects neurons in the oxygen-glucose deprivation (OGD) model. SCR-4026 can reduce the cerebral infarct volume in the rat middle cerebral artery occlusion (MCAO) reperfusion model. SCR-4026 can be used for the study of stroke .
    SCR-4026
  • HY-P10360
    Tat-βsyn-degron

    		α-synuclein Neurological Disease
    Tat-βsyn-degron is an α-synuclein knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .
    Tat-βsyn-degron
  • HY-17555
    Meclofenoxate hydrochloride

    Centrophenoxine hydrochloride

    		 nAChR iGluR Neurological Disease
    Meclofenoxate (Centrophenoxine) hydrochloride is an ester synthesized from DMAE and pCPA, capable of crossing the blood-brain barrier, and can stimulate memory and enhance cognition .
    Meclofenoxate hydrochloride
  • HY-153169
    6PPD-Q
    5 Publications Verification

    6PPD-Quinone

    		 α-synuclein Others
    6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .
    6PPD-Q
  • HY-112722
    Neurotoxin Inhibitor

    		PINK1/Parkin Neurological Disease
    Neurotoxin Inhibitor is a neurotoxin inhibitor. Neurotoxin Inhibitor promotes the expression of DJ-1 protein, reduces the level of oxidative stress, and thereby protects dopaminergic neurons. Neurotoxin Inhibitor can be used for the study of Parkinson's disease .
    Neurotoxin Inhibitor
  • HY-178153
    AMPA receptor modulator-9

    		iGluR Neurological Disease
    AMPA receptor modulator-9 is an orally active, selective positive allosteric modulator (PAM) of AMPARs with blood-brain barrier penetration. AMPA receptor modulator-9 selectively potentiates AMPAR activity in human and rat models, with an EC2x value of 0.96 μM in rat embryonic cortex primary neurons. AMPA receptor modulator-9 upregulates BDNF protein expression in rat primary cortical neuronal cultures. AMPA receptor modulator-9 enhances AMPA-mediated excitatory postsynaptic responses in rat and mice. AMPA receptor modulator-9 can be used for the study of cognitive disorders .
    AMPA receptor modulator-9
  • HY-121636S
    Resolvin D2-d5

    RvD2-d5

    		 TRP Channel Infection Neurological Disease Inflammation/Immunology
    Resolvin D2-d5 is the deuterium labeled Resolvin D2. Resolvin D2 is a metabolite of docosahexaenoic acid (DHA), with anti-inflammatory, anti-infective activities. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Resolvin D2 is a remarkably potent inhibitor of TRPV1 (IC50 = 0.1 nM) and TRPA1 (IC50 = 2 nM) in primary sensory neurons .
    Resolvin D2-d5
  • HY-151962
    JNK3 inhibitor-5

    		JNK Apoptosis GSK-3 p38 MAPK Neurological Disease
    JNK3 inhibitor-5 (Compound 22b) is a potent and selective JNK3 inhibitor with an IC50 of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable .
    JNK3 inhibitor-5
  • HY-21197
    Perfluoroenanthic acid

    Perfluoroheptanoic acid; Tridecafluoroheptanoic acid; PFHpA

    		 iGluR Neurological Disease
    Perfluoroenanthic acid (Perfluoroheptanoic acid) is a type of perfluoroalkyl substance (PFAS) that can negatively impact the development of seminiferous tubules and m6A RNA methylation in the testes of offspring mice when exposed during pregnancy, consequently disrupting spermatogenesis and leading to reproductive toxicity. Perfluoroenanthic acid alters the morphology of dendritic spines and synaptic formation in primary cortical neuron cultures, enhancing neuronal activity and synaptic transmission, and increasing the expression of excitatory synapse-related proteins Synaptophysin and PSD95 .
    Perfluoroenanthic acid
  • HY-151527
    PI3K/Akt/CREB activator 1
    3 Publications Verification

    		 Akt PI3K Epigenetic Reader Domain Neurological Disease
    PI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD) .
    PI3K/Akt/CREB activator 1
  • HY-102052
    DCEBIO

    		Potassium Channel Metabolic Disease
    DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia .
    DCEBIO
  • HY-111351
    MLK-IN-1

    		Mixed Lineage Kinase Neurological Disease
    MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1 .
    MLK-IN-1
  • HY-175824
    PSD-95/nNOS PPI-IN-1

    		iGluR NO Synthase Apoptosis Reactive Oxygen Species (ROS) Neurological Disease
    PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the PSD-95/nNOS interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (Ki = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke .
    PSD-95/nNOS PPI-IN-1
  • HY-167862
    UCM-05194

    		Endogenous Metabolite Neurological Disease
    UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases .
    UCM-05194
  • HY-P3688
    β-Amyloid (1-38)

    Aβ (1-38); Aβ38

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-38) (Aβ (1-38)) is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38) reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
    β-Amyloid (1-38)
  • HY-P3688A
    β-Amyloid (1-38) TFA

    Aβ (1-38) TFA; Aβ38 TFA

    		 Amyloid-β Neurological Disease
    β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .
    β-Amyloid (1-38) TFA
  • HY-120059
    NS4591

    		Potassium Channel Neurological Disease
    NS4591 is a modulator of calcium-activated potassium channels with activity that enhances small (SK) and intermediate (IK) conductivity. NS4591 doubled IK-mediated currents in whole-cell patch-clamp experiments at a concentration of 45 +/- 6 nM, and doubled SK3-mediated currents at a concentration of 530 +/- 100 nM. NS4591 inhibits the number of action potentials generated by suprathreshold depolarizing pulses in acutely isolated bladder primary afferent neurons. NS4591 also reduced carbakol-induced detrusor ring contraction in the rat bladder, demonstrating sensitivity to apamin .
    NS4591
  • HY-145607
    Zagociguat

    CY-6463; IW-6463

    		 Guanylate Cyclase Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Zagociguat (CY-6463) is an orally active and BBB-permeable soluble guanylate cyclase (sGC) stimulator. Zagociguat can increase cGMP levels, regulate blood pressure, improve neuronal function, reduce inflammatory responses, and exert neuroprotective and cognitive-improving effects. Zagociguat can be used in the research of neurodegenerative diseases .
    Zagociguat
  • HY-100604
    JNJ-40418677

    		γ-secretase Amyloid-β Neurological Disease
    JNJ-40418677 is an orally active modulator of γ-secretase, can cross the blood-brain barrier. JNJ-40418677 inhibits Aβ42 and NS2B-NS3 protease, with IC50s of 200 nM and 3.9 μM, respectively. JNJ-40418677 displays good biological tolerance, can be use for Alzheimer’s disease research .
    JNJ-40418677

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: